Document:

Prepared and filed by St Ives Burrups

Exhibit
    10.24

MASTER VIROLOGIC 

  SERVICES AGREEMENT

THIS
        MASTER VIROLOGIC SERVICES AGREEMENT
(“Agreement”) IS MADE THIS 22nd day of May, 2002, between Progenics Pharmaceuticals,
Inc. with an office located at 777 Old Saw Mill River Road,
Tarrytown, New York 10591 (“Progenics”) and VIROLOGIC, INC. with
an
office located at 345 Oyster Point Blvd., South San Francisco, CA 94080 (“ViroLogic”).

WHEREAS, ViroLogic is engaged in the business of
  providing clinical laboratory services; and
  
  WHEREAS,
      Progenics desires to contract with ViroLogic to provide certain clinical
      laboratory services,
        including, but not limited to its proprietary phenotypic susceptibility
        tests, including PhenoSenseTM HIV and its phenotypic Entry
        inhibitor assay, its genotypic test, GencSegTM HIV and such
        additional tests or data
        as may be requested by Progenics from time to time, and ViroLogic desires
to provide the services described herein;
  
IT IS THEREFORE AGREED AS FOLLOWS:  

  1.      VIROLOGIC
    SERVICES AND PROTOCOLS

1.1      Whenever
    Progenics desires ViroLogic to perform clinical laboratory testing services
    in connection
  with a study in which Progenics is the sponsor (“Study”), Progenics
  will provide a copy of the Study protocol (“Protocol”) to ViroLogic,
  and Progenics and ViroLogic shall agree on (a) a scope of work which sets forth
  those clinical laboratory tests and services to be performed by ViroLogic (hereinafter
  referred to as “ViroLogic Services”),
  and (b) a fee schedule. 
  1.2      For
        each Study in which ViroLogic shall provide ViroLogic Services, a Work
        Order, in the form attached hereto as Exhibit A, shall be prepared by
        the parties describing the services to be provided by ViroLogic and have
        attached to it the following schedules (the “Schedules”): A
        copy of the subject Protocol and/or ViroLogic project plan shall be attached
        thereto as Schedule 1 and; a fee schedule
        for such ViroLogic Services shall be attached thereto as Schedule 2.
        Progenics may, from time to time, in
        its sole discretion modify the Study Schedule(s) and/or
        Protocol. Upon execution by both Progenics
        and ViroLogic, each Work Order shall be subject to the terms of this
        Agreement and incorporated herein. If any terms of this Agreement are
        in conflict with any
        terms of the Work Order, the terms of this Agreement shall govern.

    1.3      (a)     Upon
        completion of ViroLogic’s testing of sample(s) for each Study, ViroLogic
        will transmit the test results to Progenics
        in a form agreed upon by the parties in advance of the provision of services
        hereunder by ViroLogic and to the appropriate principal investigator
            at each Study site by fax, electronically, mail or, for an
            additional charge, by overnight mail. Such test results shall be
            considered Confidential
        Information of Progenics subject to the
        obligations of Section 3
        hereof and Progenics may use for any purpose. ViroLogic shall not provide
        any advice, either written or oral, to any investigator or their designee(s)
        participating in the Study regarding choice of regimen, decision to switch,
        discontinue or continue therapy.

                (b)      ViroLogic
        will store samples immediately upon receipt under appropriate conditions
        to ensure their preservation until completion of testing. ViroLogic agrees
        to store the unused portion of the samples for one
          year from completion of the testing. Progenics
        will not be charged for the first year of storage but a fee for storage
        beyond such one year
        will be as agreed upon by the parties. Upon Progenics’ request ViroLogic
          will either return the samples to Progenics or dispose of the samples.
          After one
        year ViroLogic may dispose of the sample at its discretion unless Progenics
        provides alternative instructions. Progenics and ViroLogic will agree
        upon the means for and reporting of the disposal of samples.

    1.4      For
        each Study, ViroLogic will provide Progenics with a
        monthly status report summarizing the ViroLogic Services performed hereunder
and the number of patients tested at each Study site.

 

Back to Contents

2.      FEES
AND BILLING

2.1      ViroLogic
    shall charge fees for ViroLogic Services in ifie amounts agreed to by the
    parties
  in each Work Order as set forth in Schedule 2 attached to this Agreement. For
  each Work Order, ViroLogic shall submit to Progenics a monthly statement
  which reflects the ViroLogic Services rendered to Progenics by ViroLogic
  for the prior month, and the total amount due for such. ViroLogic Services.
  Progenics payment timelines shall be specified in each Work Order, and it is
  agreed that such payment timelines shall not exceed thirty (30) days from Progenics’
  receipt of a monthly statement. Invoices must be provided to Progenics no more
  than three (3) months after the date the applicable payment is earned, 

  

    2.2      If
        the scope of ViroLogic Services in any Work Order changes, or if the
        time frame for completion of such ViroLogic Services changes, Progenics
        shall so advise ViroLogic and submit such changes to ViroLogic on a form,
        the format of which is attached hereto as Exhibit B (the “Task Change
        Form”). The fees to be paid by Progenics for such ViroLogic Services
        will be adjusted in accordance with any such requested changes as mutually
        agreed upon by Progenics and ViroLogic and shall be based on those rates
        set forth in the fee schedule attached as Schedule 2 to such Work Order.
        ViroLogic may change the test fee(s) set forth in Schedule 2 no more
        than once every twelve (12) months, provided however, that ViroLogic
        may change the test fee(s) more often if ViroLogic adds antiretroviral
        agent(s) to its then-current select panel or comprehensive panel. The
        Task Change Form, upon execution by both parties, shall constitute
        an amendment to the applicable Work Order and be attached thereto.

3.    CONFIDENTIALITY

3.1      With
    respect to any and all Confidential Information (as defined below) which
    either party
  receives from the other or is generated under this Agreement, the receiving
  party agrees (i) to use the Confidential Information only in connection with
  its performance of this Agreement; (ii) to treat the Confidential Information
  as it would its own proprietary
        and confidential information; (iii) to disclose the Confidential Information
        only to employees or agents that agree to be bound by these confidentiality
        obligations and who need to know such Confidential Information in connection
        with a Study; and (iv) to take all reasonable precautions to prevent
        the disclosure of the Confidential Information to any third
        party without the prior written consent of the providing party. For the
        purposes of this Agreement, Confidential Information shall be defined
        as information (scientific or business), data, know-how, whether written
        or oral, technical or non-technical, as well as tangible materials, including
        without limitation, samples, specimens, models, drawings, or diagrams
        which a party receives from the other or other’s agent. 

  3.2      The
        receiving party shall be relieved of all obligations under this Section
        3 regarding Confidential Information which: (i) was known to the receiving
        party, prior to receipt hereunder as set forth in written records; or
        (ii) at the time of disclosure to the receiving party was generally available
        to the public, or which after disclosure hereunder, becomes generally
        available to the public, through no fault of the receiving party; or
        (iii) is hereafter made available to the receiving party from any third-party
        having a right to do so on a non-confidential basis; or (iv) is required
        by law, regulation, subpoena, government order or judicial order to be
        disclosed, provided the receiving party shall promptly notify the party
        who provided the information upon such request for disclosure and prior
        to such disclosure to permit the providing party to oppose same by appropriate
        legal action. 

4.    PUBLICATIONS

All
        of the data, including phenotypic drug susceptibility data or genotypic
        data generated by ViroLogic may be used by the parties as follows. Progenics
        may use the data, without prior approval by ViroLogic, for any purpose,
        including without limitation its purposes relating to the research, development
and marketing of its HIV/AIDS products or other antivirals. ViroLogic
    may use the data, without prior written approval by Progenics, for its purposes
    relating to research, development and marketing of phenotypic and/or genotypic
    drug susceptibility testing, antiviral therapy guidance and related products
    in an anonymous fashion which does not in any way identify or reference specific
    patients, compounds or clinical studies of Progenics. Progenics shall be
    free to publish the data in a manuscript, abstract or presentation. Progenics
    may
    provide a copy of such manuscript, abstract, or presentation to ViroLogic
    prior to submission or presentation according to customary scientific practice.
    With
    respect to any data which identifies or references specific patients, clinical
    studies or Progenics, ViroLogic may publish the data
  

   

2

Back to Contents

only after providing a copy of the manuscript, abstract or presentation materials to Progenics at least one month before publication or presentation and only after receiving Progenics’ prior approval, except that ViroLogic may not publish any manuscript, abstract or presentation that uses unpublished clinical outcome data, or identifies a drug prior to approval for marketing or identifies the clinical studies carried out pursuant to this Agreement without Progenics’ prior written consent, which consent shall not be unreasonably withheld. ViroLogic shall not issue a press release or any other document that references any Protocol or Study sponsored by Progenics, or that uses Progenics’ name or
trademarks without the prior written consent of Progenics, however, if ViroLogic is acknowledging Progenics’ contribution in a scientific paper in accordance with customary scientific practice then such acknowledgment will not require Progenics’ consent. Progenics shall not issue a press release or any other document that references or uses ViroLogic’s name or trademarks without the prior written consent of ViroLogic, however, if Progenics is acknowledging ViroLogic’s contribution in a scientific paper in accordance with customary scientific practice then such acknowledgment will not require ViroLogic’s consent.

5.      OWNERSHIP
OF MATERIALS AND INTELLECTUAL PROPERTY

5.1      In
    this agreement “Intellectual
    Property” shall mean all inventions, discoveries, work product, patents,
    design rights (registered
  or unregistered), trademarks, copyright, trade secrets and/or confidential
  know-how, technology, materials and/or, technical information developed by
  either party. 

  5.2      Progenics
      shall have no rights whatsoever in respect of or in relation to ViroLogic’s,
      nucleic acid
        based vectors, including but not limited to those constructed or utilized
        in tested performed hereunder, assay technology, testing methods, practices,
        or procedures or in the test apparatus or equipment, or any improvements
        thereto, owned or licensed by, developed by or for ViroLogic at any time,
        and Progenics hereby acknowledges that it shall not acquire any right
        in respect thereof and that all such rights and good will are and shall
        remain vested in ViroLogic.

    5.3      ViroLogic
        shall have no rights whatsoever in respect of or in relation, any of Progenics’
        compounds
        or methods of compound synthesis, or any improvements thereto, owned
        or licensed by, developed by or for Progenics at any time, and Progenics
        hereby acknowledges that it shall not acquire any right in respect thereof
        and that all such rights and good will are and shall remain vested in
        Progenics. Progenics agrees that in the event that any
        compounds or materials supplied by it to ViroLogic hereunder are or
        become approved for In Vivo use in patients ViroLogic
        may, without further approval from Progenics or cost, use such materials
        or compounds in its clinical laboratory for In Vitro use in drug resistance
        and/or drug susceptibility testing.

    5.4      ViroLogic
        retains all rights, including patent, in and to any and all viral vectors
        derived by it from a patient
        sample including but not limited to the HIV gene(s) used in the testing
        performed hereunder. Furthermore, ViroLogic
        has all right title and interest in and to the vector(s) constructed
        using the gene(s) derived from the patient sample.

    5.6      Except as specifically set forth above in sections 5.2, 5.3 and 5.4
          the parties
        shall jointly own
        all rights, including patent, in and to any and all substances derived
        from a patient sample, which are not Progenics Compounds or ViroLogic
        viral vectors,  if any which substance is
        developed or derived from Progenics samples or materials supplied hereunder,
        by either party in to the performance of this Agreement. Neither party
        shall sell, license or otberwise commercialize any such substances
without the prior written approval of the other party,  

6.       STANDARDS

6.1      Except
    as set forth herein, in performing its services hereunder, ViroLogic shall
    perform in accordance
  with established and recognized clinical laboratory testing procedures
  and with reasonable care in accordance with applicable federal, state, and
  local laws, regulations and rules, including any
  applicable Good Laboratory Practices (“GLP”). All of ViroLogic’s
  tests, assays and other activities undertaken under this Agreement shall
  comply in all material respects with all regulations and/or
  standards prescribed and/or endorsed by the College of
  American Pathologists (“CAP”). VIROLOGIC’S SERVICES
  FOR ENTRY INHIBITOR EVAULATION, INCLUDING ALL PHENOTYPIC AND GENOTYPIC TESTING

3

Back to Contents

PROVIDED
    BY VIROLOGIC TO PROGENICS HEREUNDER INCLUDING TESTS, ASSAYS AND OTHER ACTIVITIES
    WILL BE PERFORMED FOR “RESEARCH USE ONLY” AND AS SUCH, ARE NOT
    REPRESENTED TO BE AND SHALL NOT BE REQUIRED TO COMPLY WITH CAP AND/OR CLINICAL
LABORATORY IMPROVEMENT ACT REGULATIONS.

6.2      ViroLogic
    represents and warranties that it is qualified to perform the services required
    of it
  hereunder in a competent and professional manner and to satisfy the requirements
  of Section 6.1 above.

7.       INDEMNIFICATION

7.1      Progenics
    agrees to indemnify and hold harmless ViroLogic and its employees, directors,
    officers
  and agents from and against any loss, damage, reasonable cost and expense (including
  reasonable attorneys’ fees and expenses) incurred in connection with any claim
  proceeding or investigation for bodily injury or death arising out of the clinical
  study carried out pursuant to the protocol attached hereto in Schedule 1, provided
  however, that (a) ViroLogic and its employees, directors, officers and agents
  are shown to have adhered to and complied with their obligations hereunder,
  the applicable Protocol, all applicable laws, regulations and rules, and all
  directions and recommendations furnished by Progenics regarding the services
  to be provided pursuant to this Agreement, and (b) ViroLogic fully cooperates
  in the handling of any such claim, proceeding or investigation, and, in the
  event of suit, ViroLogic attends hearings and trials and assists in securing
  and giving evidence and obtaining attendance of necessary and proper witnesses.
  At ViroLogic’s request, Progenics will reimburse ViroLogic for all reasonable
  expenses incurred in connection with item (b) of this subsection 7.1. Progenics
  at its own expense shall carry out the sole management and defense of such
  claims or suits, and will provide attorneys of its sole choosing to defend
  against any such claim, proceeding or investigation. Notwithstanding the foregoing,
  Progenics shall not be obligated to ViroLogic with respect to any loss, damage,
  cost and expense relating to any claim, proceeding or investigation which is
  based upon or the result of the negligence or wrongful conduct of ViroLogic
  or its employees, directors, officers, agents, or any other third party.

    7.2      ViroLogic
        agrees to indemnify and hold harmless Progenics and its employees, directors,
        officers and agents from and against any loss, damage, reasonable cost
        and expense (including reasonable attorneys’ fees and expenses)
        incurred in connection with any claim, proceeding or investigation arising
        out
        of or relating to this  Agreement
        to the extent such claim, proceeding or investigation is based on the
        negligence or wrongful conduct of ViroLogic, its employees, directors
        and/or agents with respect to the clinical laboratory testing carried
        out by ViroLogic pursuant to this Agreement, provided however, that (a)
        Progenics and its employees, directors, officers and agents are shown
        to have adhered to and complied with their obligations hereunder, the
        applicable Protocol, all applicable laws, regulations and rules, and
        (b) Progenics fully cooperates in the handling of any such claim, proceeding
        or investigation, and, in the event of suit, Progenics attends hearings
        and trials and assists in securing and giving evidence and obtaining
        attendance of necessary and proper witnesses. At Progenics’ request,
        ViroLogic will reimburse Progenics for all reasonable expenses incurred
        in connection with item (b) of this subsection 7.2. ViroLogic at its
        own expense shall carry out the sole management and defense of such claims
        or suits, and will provide attorneys of its sole choosing to defend against
        any such claim, proceeding or investigation. Notwithstanding the foregoing,
        ViroLogic shall not be obligated to Progenics with respect to any loss,
        damage, cost and expense relating to any claim, proceeding or investigation
        which is based upon or the result of the negligence or wrongful conduct
        of Progenics or its employees, directors, officers, agents, or any other
third party.

7.3      Any
    party seeking indemnification pursuant to this Section 7 (the “Indemnitee”) shall
  notify the party from whom indemnification is sought (the “Indemnitor”)
  of Indemnitee’s notice of any claim, proceeding or investigation. Such
  notice shall (i) be in writing, (ii) be delivered to Indemnitor within ten
  (10) days of the date Indemnitee
  receives notice of such claim, proceeding or investigation, and (iii) indicate
  the nature and basis of the claim, proceeding or investigation. The indemnification
  set forth in Sections 7.1 and 7.2 shall include amounts paid in settlement;
  provided, however, that no such settlement shall be entered into without the
  consent of both parties, which consent shall not be unreasonably withheld.

4

Back to Contents

7.4      ViroLogic agrees
  to secure and maintain insurance of comprehensive general liability with limits
  of at least $1,000,000 per occurrence and in the aggregate, workers’ compensation
  insurance as required by law, and employer’s liability insurance with
  limits of at least $1,000,000 each accident and a $500,000 disease policy limit.

8.       TERM AND TERMINATION

  8.1      This
      Agreement shall become effective when it has been executed by a duly authorized
      representative
    of each party, and shall continue in force for a period of three years from
    the effective date or until terminated in accordance with Section 8.2, whichever
    occurs earlier, unless extended in writing by the parties.

  8.2      This
    Agreement may be terminated in accordance with the following provisions:

(a) This Agreement may be terminated by either
  party upon the occurrence of any material default by the other party, provided
  that the defaulting party shall be given not less than fifteen (15) days prior
  written notice of such default and the opportunity to cure the default during
  such period;

  (b) This
        Agreement may be terminated immediately by either party if the other
        party becomes insolvent, is dissolved or liquidated, makes a general
        assignment for the benefit of its creditors, or files or has filed against
        it a petition in bankruptcy or has a receiver appointed for a substantial
part of its assets.

8.3.     In
    the event this Agreement is terminated pursuant to Section 8.2, then Progenics,
    in its sole
  discretion, may specify in writing, which ViroLogic Services hereunder must
  be completed by ViroLogic, and the effective date of termination of this Agreement
  shall be extended only with respect to those ViroLogic Services and corresponding
  Work Orders specified by Progenics until they are completed. Progenics shall
  be obligated to pay for the Laboratory Services performed by ViroLogic through
  the effective date of termination as provided under paragraph 8.5.

  8.4      Progenics
        may terminate any Work Order at any time with or without cause by giving
        ViroLogic at
        least thirty (30) days prior written notice. Progenics
        shall be obligated to pay for the ViroLogic Services performed by ViroLogic
        through the effective date of termination as provided under paragraph
        8.5.

    8.5      If
        this Agreement or any Work Order(s) is terminated pursuant to this Section
        8, ViroLogic shall use its best efforts during the period between notice
        of termination and the effective date of such termination to wind-up
        all services in accordance with its responsibilities under this Agreement
        and applicable law and regulation, in order to reduce or eliminate further
        costs, and to cancel, if permitted under the terms of applicable agreements,
        any third party obligations. Within thirty (30) days after the completion
        of wind-up of the terminated ViroLogic Services (which wind-up includes
        receipt by Progenics of all ViroLogic reports and other deliverables
        prepared by ViroLogic, if any, prior to the date of termination), ViroLogic
        shall provide Progenics with a written itemized statement of all work
        performed by it in connection with the terminated services. Such statement
        shall include only those ViroLogic Services detailed in the relevant
        Work Order. ViroLogic shall be entitled to a pro rata payment based on
        the amount of ViroLogic Services provided by ViroLogic pursuant to the
        terms of this Agreement through the date of termination. If the amounts
        paid by Progenics to ViroLogic in connection with such ViroLogic Services
        exceed such pro rata amount, then ViroLogic shall promptly refund such
        excess to Progenics, and if such pro rata amount exceeds the amount already
        paid by Progenics to ViroLogic, then Progenics shall promptly pay the
        amount of such excess to ViroLogic. Any refund or payment under this
        Section 8 shall be made within thirty (30) days after Progenics’ receipt
        of ViroLogic’s itemized statement.

9.      NON-ASSIGNABILITY

  Neither this Agreement
      nor any right or interest hereunder may be assigned or transferred by either
      party without
      prior written
    consent of the other party, except this Agreement may be assigned to a party
    that succeeds to all or substantially all of a party’s business or assets
    whether by sale, merger, operation of law or otherwise.

   

5

Back to Contents

10. NOTICES

  Any notice required to be given pursuant to the
    terms and provisions hereof shall be in writing and shall be sent by overnight
    courier service or certified or registered mail to ViroLogic at:

  ViroLogic, Inc.

    345 Oyster Point Blvd.

    South San Francisco,
      CA 94080

    Attention:   Chief Executive Officer, 

  

    and with copies to:

  Vice
      President, Clinical Research

Vice President and General Counsel

and to Progenics at:
  777 Old
        Saw Mill River Road

    Tarrytown, New York 10591 

and with copies to:
  William
        Olsen, Vice President of Research and Development 

    Phillip Yachmetz, Vice President and General Counsel
        

11.      INDEPENDENT
RELATIONSHIP

For
    purposes of this Agreement, ViroLogic, its employees and any other individuals
    assigned by them to perform services
    under this Agreement
  (“Staff Members”) shall not be deemed agents, servants, partners,
  joint venturers or employees of Progenics. Thus, they do not have the authority
  to take action on Progenics’ behalf or to bind  Progenics without
  Progenics’ prior written consent. ViroLogic and its Staff Members are
  acting in the capacity of independent contractors of Progenics.  Progenics
  is not responsible for withholding, and shall not withhold, taxes of any kind
  from any payments it owes to ViroLogic. ViroLogic is responsible to provide
  any and all compensation, benefits and/or insurance to its Staff Members. It
  is also understood and expressly acknowledged that neither ViroLogic nor its
  Staff Members are eligible to participate in, nor are they eligible for coverage
  under, any of Progenics’ benefit plans, programs, employment policies,
  procedures or workers’ compensation insurance. In consideration of Progenics’ performance
  hereunder, Progenics shall be released from any liability arising from Progenics’ failure
  to provide such plans, programs,
  policies,
procedures and workers’ compensation insurance.

12.       DELAYS

12.1      Neither
    party shall be liable for the failure to perform its obligations under this
    Agreement
  if such failure is occasioned by a contingency beyond such party’s reasonable
  control, including but not limited to strikes or other labor disturbances,
  lockouts, riots, wars, earthquakes, fires, floods or storms. A party claiming
  a right to excused performance under this Section 12 shall immediately notify
  the other party in writing of the extent of its inability to perform, which
  notice shall specify the occurrence beyond its reasonable control that prevents
  such performance, 
  12.2      If
          Progenics determines and acknowledges in writing that ViroLogic Services
          will be delayed for unavoidable justified reasons, ViroLogic
          will be obligated to complete its duties and obligations hereunder
by that extended date.

6

Back to Contents

13.      BENEFIT

This
    Agreement is intended to inure only to the benefit of ViroLogic and Progenics.
    This Agreement is not intended to create, nor shall be deemed or construed
    to create, any
  rights in any third parties.

14.      HEADINGS

The
    headings appearing in this Agreement are for convenience and reference only
    and are not intended to and shall not, define
  or limit the scope of the provisions to which they relate.

15.      ENFORCEABILITY/SEVERANCE
CLAUSE

The invalidity or unenforceability of any terms
  or provisions hereto in any jurisdiction shall in no way affect the validity
  or enforceability of any of the other Terms or provisions in that jurisdiction,
  or of the entire Agreement in any other jurisdiction.

16.      INTEGRATION

This
    Agreement constitutes the entire agreement between the parties on the subject
    matter hereof and supersedes all prior contracts, agreements, and understandings
    relating to the same subject matter between the parties.

17.      WAIVER

No
    course of dealing between the parties or any delay on the part of either
    party in exercising any rights it may have under this Agreement shall operate
    as a waiver of any of the rights of such hereunder.

19.      MODIFICATION

Except
    for the Protocol and/or Study Schedule(s) which may be modified in accordance
    with Section 2.2, this Agreement may not be modified except in a writing
    signed by an authorized representative of each party.

20.      SURVIVAL
OF PROVISIONS

Sections
    3, 4, 5, 7, 8, 10, 11, 18, 20 and 21 hereof shall survive termination of
    this Agreement. 

21.      APPLICABLE LAW

This
    Agreement shall be construed under, and the rights of the parties hereto
    shall be governed under the laws of the State of Delaware without giving
    effect to its choice of law principles.

22.      EXECUTION

This Agreement may be executed by way of faxed signatures
  exchanged between the parties. If the parties choose to execute via faxed signatures,
  the Agreement shall be fully executed and effective upon the receipt by both
  parties of a faxed signature from the other upon a complete copy of this Agreement.
  The parties may then also exchange hard signature copies, but any failure to
  do so shall not affect the execution or effectiveness of this Agreement.

  IN WITNESS
        WHEREOF, the parties have caused this Agreement to be executed in their
        names as their official acts by their respective representatives, each
        of whom is duly authorized to execute the same.

7

Back to Contents

	PROGENICS
    PHARMACEUTICALS, INC. 	VIROLOGIC, INC.
	 	 
	By:  /s/
          Philip K. Yachmetz                                   	By:  /s/
          William D. Young                      
	 	 
	Printed Name: Philip
    K. Yachmetz                 	Printed Name: William
          D. Young    
	 	 
	Title: Vice
    President and General Counsel    	Title: Chairman
          & CEO                     
	 	 
	Date: June 4,
          2002                                             	Date: 5/23/02
                                   

 

8

Back to Contents

EXHIBIT A

SAMPLE
FORMAT FOR WORK ORDERS

	Work
            Order # —

    

 

This
        Work Order is issued pursuant to the Master ViroLogic Services Agreement,
dated as of __________, between
      PROGENICS PHARMACEUTICALS with an office located at 209 Perry Parkway,
      Gaithersburg, MD 20877 (“Progenics”) and VIROLOGIC, INC. with
      its office and place of business located at 345 Oyster Point Blvd, South
      San Francisco, CA 94080 (“ViroLogic”) (the “Agreement”),
    and incorporates all of the terms and conditions therein. The parties agree
    that ViroLogic shall perform the services in accordance with this Work Order
      using, if applicable, the Material provided by Progenics hereunder,
      subject to all of the terms and conditions of the Laboratory Service Agreement
      effective January 10, 2002 between the parties. The Work Order is incorporated
      in and made a
part of the Laboratory Service Agreement.

	Work
          Order Number: ______	Study Number: ________________________
	 	 

	Name
          of ViroLogic Project
Manager: ________________________________________________________________________
	 	Phone: ______________________________
	 	Facsimile: ____________________________
	 	 Email: _______________________________

Materials Supplied:

_______________________________

ViroLogic Services (Scope of Work)

ViroLogic
        shall provide those ViroLogic Services listed herein. ViroLogic acknowledges
        and agrees that the ViroLogic Services listed herein are customarily
        offered by ViroLogic and ViroLogic is capable of performing same in accordance
with the terms of the Agreement.

_____________________ Clinical
    Leader:

Correspondence
    and testing results will be addressed to ___________________ ’ Clinical
    Leader. 

Name ____________________________________________

Title, Department____________________________________

 Address
    __________________________________________

City State
    ZIP ______________________________________

Tel: ____________________________

Fax: __________________
    Progenics ___________________

Email: ____________________________________________

Compensation:

ViroLogic shall charge fees for the ViroLogic Services provided pursuant to the Work Order in the amounts set forth in Schedule 2, or for an amount as agreed upon by both parties. 

  __________________
  shall pay ViroLogic, Inc. in consideration
      for the performance of the testing services described above in Services,
      as acceptable according to the terms of the Laboratory Services Agreement
      and corresponding work order for each project. Additional fees for electronic
data delivery or other project management and

9

Back to Contents

programming services will be determined according to the fee schedule as set forth in the Laboratory Services Agreement.

For
        Work Orders between ViroLogic and Progenics, ______________________ agrees
    to pay any undisputed amounts specified in the monthly statement referred
    to in Section 2.1 of the Agreement within thirty (30) days after ________________________receipt
of such statement.

Payment
        as set forth in this Work Order shall constitute full payment for the
        Study and the ViroLogic Services provided hereunder, and Progenics shall
        have no other payment obligations hereunder to ViroLogic or any other
third party.

I.      All
    invoices to ______________________ shall
be sent at the attention of: 

Name: _______________________________________
  Address:
____________________________________

  The
      name and address of the payee for all payments due to ViroLogic hereunder
      is: 

  
    Attn: Billing Department

    ViroLogic, Inc.

    345 Oyster Point Blvd.

    South San Francisco, CA 94080

  

Tax
    ID Number of the payee: 94-3234479________________________________

10

Back to Contents

2.        Site mailing
    address for correspondence.

_____________________________________
  _____________________________________

    _____________________________________

_____________________________________

This Work
    Order is entered into and made effective as of _____________________________
    .

 Accepted and Agreed to by:

	PROGENICS
        PHARMACEUTICALS, INC. 	VIROLOGIC, INC.
	 	 
	By:  /s/
          Philip K. Yachmetz                                   	By:  /s/
          William D. Young                      
	 	 
	Printed Name: Philip
          K. Yachmetz                 	Printed Name: William
          D. Young    
	 	 
	Title: Vice
          President and General Counsel    	Title: Chairman & CEO                     
	 	 
	Date: June 4,
          2002                                             	Date: 5/23/02
                                             

 

11

Back to Contents

SCIEDULE 1 to work Order #
_____

STUDY PROTOCOL

 

 

 

 

 

 

 

 

 

 

Back to Contents

SCHEDULE
    2 to WORK ORDER # ____

FEE SCHEDULE

 

	Phenotypic
    Testing Fee Summarv	 
	 	 
	Entry
          Assay (up to six drugs)       

    	$1,000.00   
	 	 
	Standard
          PhenoSenseTM HIV Select Panel*

          For Protease and RT Drugs    

    	$775.00
	 	 
	Standard PhenoSenseTM
    HIV Comprehensive Panel*

    For Protease and RT Drugs    	$955.00 
	 	 
	Custom
PhenoSenseTM HIV Panels

For Protease and RT
Drugs 

    	 

	•	From 1 to 6 drugs
    in panel* *           	$600.00
	 	•	7-12 drugs in panel**	$775.00
	 	•	Each additional drug
    above 12 drugs**	$60.00
	 	•	**Additional cost
    for any novel drug included in panel	$300.00/per
    drug, per test 
	 	 	 	 
	Repeat testing of
    cell assay portion of PhenoSense using previously created plasnaid	 
	 	•	One drug**	$250.00
	 	•	Two drug**	$450.00 
	 	•	Three to six drugs**	$600.00
	 	•	Seven to twelve drugs**	$775,00
	 	•	Each additional drug
    above 12 drugs**	$60.00
	 	•	**Additional cost
    for any novel drug included in tested drugs	$300.00/per drug,
    per test
	 	 	 	 
	Additional
    Costs for Custom Test Requests 	 
	 	 	One time set-up/automation
    fee for novel drug	$5,000.00/drug
	 	 	 Use of library specimen
    from ViroLogic’s library	$1,000.00/specimen 
	 	 	(clinical sample or site-directed
    mutant)
	 
	 	 	One time design and
    development fee for novel site-directed mutant      	$5,000.00/SDM
	 	 	 	 
	Genotypic Testing
    Fee Schedule	 
	 	 	 	 
	 	•	Standard GeneSegTM
    HIV Assay*      	$495.00
	 	 	For Protease and
    RT Drugs	 

* Standard Panels refer to the drugs available in each assay as sold and marketed by ViroLogic for the patient testing market at the time of the study.

* The costs for providing testing results by overnight mail shall be borne by Customer, if such delivery is requested by Customer

 

Back to Contents

	Viral
    Load Testing Fee Schedule	 
	 	 
	 	•	Amplicor
    HIV-1 Monitor- Extended Range     	$200.00
	 	•	Amplicor HIV-1 Monitor-
    Ultrasensitive     	$235.00

 

* Standard
        Panels refer to the drugs available in each assay as sold and marketed
by ViroLogic for the patient testing market at the time of the study.

* The costs for providing testing results by overnight mail shall be borne by Customer, if such delivery is requested by Customer

 

Back to Contents

	Other
    Testing Fees
	 	 	 
	 	•	Partial
        fee for un-acceptable samples. A fee will be charged by ViroLogic in
        the event that a testing result is not obtained due to low viral load
        (<500
copies/mil) or improperly collected and handled specimens.       
	 	 	•	$500.00
    if phenotype and genotype or phenotype alone ordered	 
	 	 	•	 $250.00 if
    genotype only ordered	 
	 	 	 	 	 
	 	•	Additional Patient
    Reports     	$25.00
per report
	 	 	One copy of the paper
        patient report is included in testing fee. There will be a charge for
    each additional copy to be reported out.
	 	 	 	 	 
	Programming
    and Project Management Services	 
	 	 	 	 	 
	Customization
    of data management, data analysis, data reporting and other such services.	 
	 	 	 	 	 
	 	•	  Programming	$100.00 per
    hour
	 	•	Electronic
          Data Deliverable (EDD)	$200.00
per file
	 	•	Other Services	$100.00 per hour 

Formal Study Report

The basic
    fee for a formal written study report, if requested, is $ 5000, plus additional
    time or services as may be required to prepare report in a format to be defined
jointly by Pro genics and VIROLOGIC.

All
drugs manufactured, marketed or under development by _Progenics_ to be used and
      tested in PhenoSenseTM HIV will be supplied to ViroLogic at no
charge.

Virologic,
    Inc. and Progenics will develop and agree to project plans that describe
    the scope of work, including Programming and Project Management Services,
for each study.

 

Back to Contents

Exhibit B

TASK CHANGE FORM

	Study
    Name:	Protocol
    Number:
	 	 
	_____________________
        Contact:

    Name:___________________________________	ViroLogic Contact:

    Name:__________________________________
	 	 
	Title: _______________________________	Title: _____________________________
	 	 
	Telephone
No. ________________________	Telephone
No. _______________________
	 	 
	FAX No. ____________________________	FAX No. ___________________________
	 	 
	
	

	Change
        Order (describe all tasks and services, associated timelines) and responsible
    person(s)/party):
	 

	Task
    Description	 	Cost
	 	 	 
	
	 	

	 	 	 
	
	 	

	 	 	 
	
	 	

	 	 	 
	
	 	

	 	 	 
	

    	 	

    
	 	 	 
	
	 	

	 	 	 
	
	 	

	 	 	 
	For additional space,
        use separate page.

    

           	

    	 
	
	
	

	 	 	 

	Authorized
    and Agreed:	 
	 	 
	By: ____________________________	By: ____________________________
	 	 
	Title: ___________________________	Title: ___________________________
	 	 
	Date: ___________________________	Date: ___________________________
	 	 
	
    
	

	 

 

Back to Contents

Attachment A 

Drug Susceptibility
      Panels

	Select
        Panel
(12 drugs)      	Comprehensive
    Panel (16 drugs)
	 	 
	NRTI	NRTI
	Abacavir
- ABC	Abacavir
- ABC
	 	 
	Didanosine
– ddI	Didanosine
- ddI
	 	 
	Lamivudine
- 3TC	Lamivudine
- 3TC
	 	 
	Stavudine
- d4T	Stavudine
- d4T
	 	 
	Zidovudine
- ZDV	Zalcitabine
- ddC
	 	 
	 	Zidovudine
- ZDV
	 	 
	 	Tenofovir - TFV
	 	 
	NNRTI	NNRTI
	Efavirenz – EFV      	Delavirdine - DLV
	 	 
	Nevirapine - NVP      	Efavirenz - EFV
	 	 
	 	Nevirapine - NVP
	 	 
	PRI	PRI
	Amprenavir – AMP	Amprenavir - AMP
	 	 
	Indinavir – IDV	Indinavir - IDV
	 	 
	Nelfinavir
– NFV      	Lopinavir - LPV
	 	 
	Ritonavir
– RTV      	Nelfinavir - NFV
	 	 
	Saquinavir
– SQV      	Ritonavir - RTV
	 	 
	 	Saquinavir
- SQV

 

 

Back to Contents

Attachment B

Procedure for the Collection, Handling and Shipment of Specimens to ViroLogic,
    Inc. for Clinical Research Testing

This
        document describes the requirements for collection, handling, and shipment
        of blood samples prior to testing in the PhenogenseTM HIV and GeneSegTM
        MV assays. The PhenoSenseTM HIV assay is intended for use in the evaluation
        of the phenotypic susceptibility of HIV-1 in plasma to antiviral drugs.
        The GeneSeqTM HIV assay is intended for use in identifying specific genetic
mutations in HIV-1 that have been associated with antiviral drug resistance.

HIV
        RNA is especially vulnerable to degradation, therefore proper collection
        and handling of blood specimens is essential for successful performance
of these assays.

Specimen Collection:

Whole blood should be collected in sterile tubes containing EDTA as the anticoagulant (lavender top or PPT). 

Specimen
    Volume Required for Testing:

	•	3 mL of plasma is
    requested for optimal performance of these assays. 
	 	Minimum
    volume accepted: 1.5 – 2.0 mL

	 	 
	Specimen Processing:
	 	 
	•	Draw blood in a sterile
        tube containing EDTA anticoagulant (lavender top or
PPT).
	 	 
	•	Centrifuge
blood within 6 hours of collection. Centrifuge
whole blood at 1000-1200 x g at room temperature for 10-15 minutes.
	 	 
	•	Immediately after
        centrifugation remove plasma from cells and transfer to a screw cap top
        tube.
	 	 
	•	Immediately freeze plasma sample at or below -20°C
    in a standard laboratory freezer.
	 	 
	•	DO NOT THAW SAMPLE
    AFTER FREEZING!
	 	 
	 Specimen Packaging:
	 	 
	•	Transportation of
        whole blood or plasma must comply with country, federal, state and local
    regulations for the transport of infectious agents.
	 	 
	•	Plasma must be transported
    frozen on dry ice.
	 	 
	•	Properly package
    specimens to ensure safe arrival to ViroLogic.
	 	 
	•	Enclose a completed
    [Test Requisition Form) or [Spreadsheet] with each shipment.
	 	 
	•	E-mail ViroLogic
        (receiving@virologic.com) the following information prior to
    each shipment:

 

Back to Contents

	 		Study Name:      (PJXXXXX)
    
	 		Investigator name
    and address
	 	 	 
	 		Contact person, phone
    and fax number (for specimen related questions)
	 	 	 
	 		Number of specimens
    enclosed
	 	 	 
	 		Airbill number and
    name of overnight service 
	 	 	 
	Sample Shipping:
	 	 	 
	•	Ship
        specimens to ViroLogic to allow for receipt on Monday
        through
Saturday only.
	 	If shipping on Friday
      please check airbill for Saturday delivery.

    
	 	 	 
	•	If delivery
        will occur or be affected by a holiday, please call [Name of Project
    Manager] at (650) 635-1100 to ensure proper delivery.
	 	 	 
	•	Complete the airbill
    and Shipper’s Declaration of Dangerous Goods.
	 	 	 
	•	Send all specimens
    to the following address:
	 	 	 
	 	 	ViroLogic Clinical
    Reference Laboratory 

    345 Oyster Point Blvd. 

    South
      San
Francisco, CA, 94080 

Attn: [Name of Project Manager] 

Phone:      (650)     635-1100,     FAX:     (650)     615-0177,     E-Mail:     receiving@virologic.com

 

19Agreement of Purchase and Sale

To:Compuquest Inc. ("Compuquest")

Dated:October 21, 2003

WHEREAS:

1. Compuquest carries on a computer reseller business (the "Business") out of
   premises located at 60 Yonge Street, # 1001, Toronto, Ontario,.M5E 1H5

2. International Mount Company Inc., or an entity designated by International
   Mount Company Inc.("International ") wishes to acquire all of the assets of
   the Business upon the terms and subject to the conditions hereinafter set
   forth.

AGREEMENT:

3. The total purchase price for all of the operating assets of the Business,
   including, inter alia, all work in progress, inventory, furniture, fixtures
   and supplies is to be $292 402 allocated as follows:

        a) Accounts receivable                              $272,902
        b) Inventory                                           9,500
        c) Property and equipment                             10,000
        d) Goodwill, including the name Compuquest                 1

4. The purchase price for the assets shall be paid as follows:

        a) $10 in cash or by certified check or bank draft as a deposit upon
           execution of this Agreement, to be held by the lawyers for
           Compuquest, in trust, and paid to Compuquest on closing.
           In the event the transaction fails to close if one of the
           conditions of the agreement is not met through no fault of
           International, the $10 is returned to International, and
           otherwise is for the account of Compuquest.

        b) $292,402 by assuming the liabilities of Compuquest allocated as
           follows:
                 i) Bank indebtedness                       $101,988
                ii) Accounts payable                         190,414

<PAGE>

        c) Consummation of the sale, with payment by the Buyer of the balance
           of the purchase price by the assumption of the liabilities
           aforesaid, and the execution and delivery of the closing documents
           will take place on or before October 31st, 2003 ("Closing")

5. Compuquest promises and agrees to convey good, clear, and marketable title
   to all the assets and property to be sold hereunder, the same to be free and
   clear of all liens and encumbrances, other than liens and encumbrances
   directly related to the liabilities being assumed by International. Full
   possession of said property will be delivered in the same condition that
   it is now, reasonable wear and tear excected.

CONDITIONS OF AGREEMENT:

This agreement is conditional upon International, acting reasonably, satisfying
itself as to the following matters, and that such matters are true at the
time of Closing:

6. That International will agree to retain the employees of the business listed
   below ("Employees"), and that those Employees shall have agreed to be
   employed by International on the same terms on which they are currently
   employed. (Randal Kalpin, Steven Gryfe, Stephen LaSalle)

7. The balance of the employees of Compuquest not being hired by International
   shall be the responsibility of Compuquest.

8. That the books and records of Compuquest are correct and accurately reflect
   the business of Compuquest in all material aspects.

9. That the material contracts of Compuquest are assignable to International.

International has completed its due diligence and is satisfied on all matters.
All due diligence matters are for the benefit of International and have been
waived by International.

<PAGE>

10. On Closing, Compuquest will provide such representations and warranties
    as counsel for International may reasonably require, stating that they have
    the authority to sell the assets of the Business and that there are no
    adverse claims that have not been disclosed and that may affect the
    property, and that they have complied with the provisions of the Bulk
    Sales Act.

11. The Closing of this transaction is contingent upon the following
    conditions:

        a) No material adverse change in the business of Compuquest

        b) Completion of proper legal documentation as required by
           International 's counsel acting reasonably.

Article 1 CONFIDENTIALITY

12. In connection with its due diligence investigations, International agrees
    not to use any of Compuquest' confidential information for any purpose
    other that the exclusive purpose of evaluating the possibility of entering
    into a definitive Agreement with the Corporation with respect to the
    proposed transaction.  The term "confidential information" means such
    information that is not in the public domain that Compuquest furnishes
    to International, regardless of whether specifically identified as
    confidential, but does not include information that is generally in the
    public domain.

Dated the 21st day of October, 2003

The International Mount Company Inc.

        Per: /s/ Stuart Turk
            ----------------------------
             Stuart Turk - President

Accepted this 21st day of October, 2003

Compuquest Inc.

        Per: /s/ Randal A. Kalpin
            ----------------------------
             Randal A. Kalpin - President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]